Skip to content

2 results for "Meta-analysis: what did research on ayahuasca find in january 2026?"

Ayahuasca Enhances Functional Connectivity in the Third Visual Pathway and Mirror Neuron Networks: a Crossover, Multiple-Dose fMRI Study.

Social cognitive and affective neuroscience January 31, 2026 Carla Soares, Gisela Lima, Marta Teixeira et al. 1 citation

A pharmacoimaging study examined how ayahuasca affects a brain region involved in social perception, the posterior superior temporal sulcus (pSTS), which is part of the third visual pathway. Twelve healthy volunteers received two doses of ayahuasca (0.5 mg/kg and 0.8 mg/kg DMT) or a placebo in a crossover design. The higher dose increased connectivity of the right pSTS with visual and mirror-neuron brain regions. This enhanced connectivity correlated with stronger perspective-taking experiences. Participants also reported improved social relationships one week later, even though acute effects were minimal. The findings suggest ayahuasca strengthens early social information processing through the third visual pathway and mirror-neuron systems, offering a basis for its prosocial therapeutic effects.

The therapeutic potential of ayahuasca in depression, generalized anxiety, and substance use disorders: modulation of the depressive burden in a longitudinal study.

Frontiers in psychiatry January 1, 2026 Gláucio Silva Camargos, Geraldo Magela De Faria Júnior, Marcelo Lourenço et al.

Over six months, depressive symptoms decreased significantly in 280 adults with depressive, anxiety, or substance use disorders after ritualistic ayahuasca use combined with psychotherapeutic support. Scores on the Montgomery-Åsberg Depression Rating Scale dropped shortly after the intervention and remained lower for up to 180 days, though individual responses varied. The findings suggest that ayahuasca-assisted therapy can reduce depression and anxiety and may help treat substance dependence. Variability in outcomes indicates that psychodynamic factors, including integration of the psychedelic experience and ongoing therapeutic support, are crucial for effectiveness. The work supports developing personalized psychedelic-assisted treatment protocols for complex psychiatric conditions.